Evaluation of Systolic Function in Heart Failure With Middle Ejection Fraction by 3D Speckle Tracking Imaging

NCT ID: NCT04949997

Last Updated: 2021-07-02

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 130 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2017-10-01
• Study Completion Date: 2019-05-31

Brief Summary

In 2016, the European Heart Association defined the median ejection fraction heart failure for the first time. More research is needed to improve our understanding of this population, so as to make the best clinical decision and improve the prognosis. In this study, 3D-STI was used to evaluate left ventricular systolic function in heart failure with median ejection fraction.

Detailed Description

As the final manifestation of cardiovascular disease and the main cause of death, heart failure is one of the important challenges threatening human health in the 21st century. In 2016, the European Heart Association proposed a new classification standard for heart failure. In particular, for the first time, heart failure with median ejection fraction has been clearly defined. These patients have received more and more attention, but there are still relatively few studies on them. More research is needed to improve our understanding of this part of the population in order to make the best clinical decisions and improve the prognosis. 3D speckle tracking technology is a new technology developed on the basis of real-time three-dimensional echocardiography and speckle tracking technology. It is gradually recognized in the evaluation of left ventricular systolic and diastolic function, especially in the evaluation of cardiotoxicity of chemotherapy drugs. At present, the application of 3D-STI in the evaluation of left ventricular systolic function in heart failure with median ejection fraction is limited and needs further study.In this study, 3D-STI was used to evaluate left ventricular systolic function in heart failure with median ejection fraction.

Conditions

Heart Failure

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: PROSPECTIVE

Study Groups

control

patients without heart failure

No interventions assigned to this group

HF

patients with heart failure

diagnose

Intervention Type: OTHER

HF was divided into HF with preserved ejection fraction, HF with median ejection fraction and HF with reduced ejection fraction.

Interventions

diagnose

HF was divided into HF with preserved ejection fraction, HF with median ejection fraction and HF with reduced ejection fraction.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

Meeting the diagnostic and classification criteria of heart failure proposed in the 2016 ESC guidelines for the diagnosis and treatment of acute / chronic heart failure

Exclusion Criteria

1. acute or chronic infectious diseases;

2. COPD, chronic bronchitis, emphysema and other serious lung diseases;

3. Autoimmune diseases;

4. Malignant tumor;

5. Acute, chronic liver disease or other reasons lead to abnormal liver function (transaminase is more than 3 times of normal value);

6. Acute and chronic kidney disease, end-stage renal disease (serum creatinine > 220 μmol/L, or creatinine clearance rate < 30 ml/min);

7. Heart valve disease;

8. Severe arrhythmia;

9. The image quality of echocardiography was poor when it was larger than three sections;

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Peking University Third Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Peking University Third Hospital

Beijing, Beijing Municipality, China

Countries

China

Other Identifiers

IRB00006761-M2017152

Identifier Type: -

Identifier Source: org_study_id